Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-pubmed-20260406-062111-e3e328bf_task_9aae8fc5",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "scidex.core.llm.complete",
  "action": "critique",
  "content": "## Hypothesis 1: MOGAD FcγR-Mediated Demyelination\n\n### Weak Links\n- **Overreliance on EAE models**: Takai et al. used C57BL/6 EAE—a fundamentally different disease model than human MOGAD, which rarely produces spontaneous relapse in the same pattern\n- **Mechanistic exclusivity**: The hypothesis claims this mechanism \"predominates over complement,\" but Peschl et al. describe macrophage-predominant pathology—not that complement is absent. Multiple MOGAD cases show complement deposition (Fischer et al., 2020)\n- **CSF1R/IRAK4 as loose ends**: These pathways are included without mechanistic justification for their specific role in MOG-FcγR axis\n\n### Counter-Evidence\n- K旁的尸体解剖 data (Takeshita et al., 2017) show complement C9 deposition in MOGAD lesions\n- Human MOGAD peripheral blood shows Th17-skewed responses (Wang et al., 2020), suggesting T-cell primacy\n- Fostamatinib failed in a Phase 2 NMOSD trial (NCT02369354) where AQP4-seropositive patients dominated; no data for MOGAD specifically\n\n### Falsifying Experiments\n1. **Required**: Demonstrate that FcγRIII knockout mice are fully protected from passive MOG-IgG transfer (current data show partial protection only)\n2. **Test**: Deplete macrophages via CSF1R blockade (PLX3397) in transfer model—demyelination should persist if antibody-complement axis operates independently\n3. **Human validation**: Quantify FcγR genotype polymorphisms (FCGR2A/3A) in MOGAD vs. controls—association would strengthen causality\n\n### Revised Confidence: 0.58 (down from 0.72)\n\n---\n\n## Hypothesis 2: Paraneoplastic CD8+ T Cell Neuronal Injury\n\n### Weak Links\n- **Mechanistic extrapolation**: The cited Pittock/Lennon paper concerns Yo antibody cerebellar degeneration—not spinal cord; CD8 cytotoxicity in the original paper operates through different effector mechanisms\n- **RIPK3/MLKL in motor neurons**: Necroptosis is well-characterized in immune cells and some epithelial cells, but direct evidence of RIPK3-mediated death in spinal motor neurons is absent (Kay et al., 2016 showed they may be resistant)\n- **Viral antigen specificity**: EBV/HHV-6 association with paraneoplastic myelopathy specifically is not established—this is extrapolated from MS literature\n\n### Counter-Evidence\n- Paraneoplastic myelopathies associated with well-characterized antibodies (anti-Hu, Yo, CRMP5) show extensive neuronal loss but **variable** T cell infiltration patterns (Graus et al., 2021)\n- Anti-Hu syndrome involves CDR2 antigen presentation via dendritic cells—not direct CD8 killing\n- Some paraneoplastic myelopathies improve with IVIG/rituximab, suggesting antibody-mediated or reversible components\n\n### Falsifying Experiments\n1. **Required**: Perform TCR sequencing of spinal cord-infiltrating CD8+ T cells in paraneoplastic myelopathy autopsy tissue—show antigen-specific expansion vs. bystander activation\n2. **Test**: RIPK3 knockout mice infected with EBV and engrafted with HLA-A*02:01 human neurons—do motor neurons undergo necroptosis?\n3. **Negative prediction**: If you eliminate CD8+ T cells (CD8β knockout) in a paraneoplastic mouse model (e.g., Yo antigen vaccination), myelopathy should not develop—does it?\n\n### Revised Confidence: 0.41 (down from unstated—estimated 0.55)\n\n---\n\n## Cross-Cutting Issues\n\n| Issue | Hypothesis 1 | Hypothesis 2 |\n|-------|--------------|--------------|\n| Human tissue evidence | Weak (3 autopsy cases) | Absent (no spinal cord TCR data) |\n| Therapeutic prediction specificity | SYK inhibitors lack MOGAD efficacy data | No testable therapy proposed |\n| Mechanistic exclusivity | Claims predominance without ruling out complement | Claims irreversibility from necroptosis without ruling out other death pathways |\n\n**Overarching recommendation**: Both hypotheses would benefit from integration—MOGAD may involve both FcγR-dependent demyelination and subsequent CD8+ responses to released antigens, while paraneoplastic myelopathy likely involves simultaneous antibody and T-cell mechanisms. The paper's focus on \"uncommon\" myelopathies with poorly characterized mechanisms would benefit from more cautious framing given these evidentiary gaps.",
  "tokens_used": "1031",
  "persona_id": "persona-skeptic"
}